021-51111890
购物车（）
sales@molnova.cn
Pergolide mesylate salt
CAS No. 66104-23-2
Pergolide mesylate salt ( LY127809; NSC 319773 )
产品货号. M15516 CAS No. 66104-23-2
PERGOLIDE MESYLATE is a long-acting dopamine agonist which has been used to treat parkinson disease and hyperprolactinemiabut withdrawn from some markets due to potential for heart valve diseases.
纯度: >98%(HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥381 | 有现货 |
|
| 10MG | ￥543 | 有现货 |
|
| 25MG | ￥948 | 有现货 |
|
| 50MG | ￥1515 | 有现货 |
|
| 100MG | 获取报价 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Pergolide mesylate salt
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述PERGOLIDE MESYLATE is a long-acting dopamine agonist which has been used to treat parkinson disease and hyperprolactinemiabut withdrawn from some markets due to potential for heart valve diseases.
-
产品描述PERGOLIDE MESYLATE is a long-acting dopamine agonist which has been used to treat parkinson disease and hyperprolactinemiabut withdrawn from some markets due to potential for heart valve diseases.
-
同义词LY127809; NSC 319773
-
通路Endocrinology/Hormones
-
靶点5-HT Receptor
-
受体5-HT receptor; Adrenergic receptor; Dopamine receptor
-
研究领域Neurological Disease
-
适应症——
化学信息
-
CAS Number66104-23-2
-
分子量410.59
-
分子式C20H30N2O3S2
-
纯度>98%(HPLC)
-
溶解度DMSO 10 mg/mL;Water 82 mg/mL
-
SMILES[H][C@@]1(N(CCC)C[C@H](CSC)C[C@@]12[H])CC3=CNC4=C3C2=CC=C4.CS(=O)(O)=O
-
化学全称8-beta-((Methylthio)methyl)-6-propylergoline methanesulfonate
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Fuller RW, et al. J Pharm Pharmacol. 1985 Apr;37(4):268-70.
产品手册
关联产品
-
Azaphen
Azaphen is the reuptake of serotonin inhibitor.with antidepressant action and has sedative effects suggesting antihistamine activity.?
-
4F 4PP oxalate
4F 4PP oxalate is a 5-HT2A antagonist.
-
Histamine
Histamine is an organic nitrogenous compound involved in local immune responses as well as regulating physiological function in the gut and acting as a neurotransmitter.
